Christopher Chai
Director/Board Member presso SURROZEN, INC.
Profilo
Chris is a Venture Partner based in our San Francisco office, working with portfolio companies on their engagement with Wall Street and their overall financing strategy and execution.
Chris spent over 20 years in executive management at biotech companies and investment banking.
He has taken companies public, from both the company and the banking side, and has sold two companies in billion-dollar M&A transactions.
Chris raised $2.3BN in over 20 financing transactions which included venture rounds, crossovers, IPOs, follow-ons, converts and equity lines of credit.
He was instrumental in gaining equity research coverage from 30 sell-side analysts, as well as developing a broad network of private and public institutional life sciences investors.
Chris has built and evolved his teams from private to public company finance organizations.
In addition, he was involved with scaling one company to over 700 employees including the buildout of a US specialty salesforce.
Chris previously was selected to Institutional Investor’s America’s Best CFOs list for the Biotechnology sector.
He currently sits on the Board of Surrozen, Inc.
Prior Executive roles:
CFO at Principia Biopharma (PRNB), acquired by Sanofi; CFO at MAP Pharmaceuticals (MAPP), acquired by Allergan; Vice President, Treasury and Investor Relations at CV Therapeutics (CVTX), acquired by Gilead
Prior Investment Banking roles:
JP Morgan (San Francisco and New York)
Education:
Chris received his BS in Operations Research and Industrial Engineering from Cornell University
Posizioni attive di Christopher Chai
| Società | Posizione | Inizio |
|---|---|---|
| SURROZEN, INC. | Director/Board Member | 01/04/2021 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Private Equity Investor | 11/02/2021 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 06/05/2021 |
SR One Capital Management LP
 SR One Capital Management LP Investment ManagersFinance SR One Capital Management LP (SR One) is a venture capital firm founded in 2020. The firm is headquartered in Redwood, California. | Private Equity Investor | 01/01/2021 |
Precedenti posizioni note di Christopher Chai
| Società | Posizione | Fine |
|---|---|---|
| PRINCIPIA BIOPHARMA INC. | Director of Finance/CFO | 28/09/2020 |
Transcriptx, Inc.
 Transcriptx, Inc. BiotechnologyHealth Technology Part of ReCode Therapeutics, Inc., Transcriptx, Inc. develops mRNA therapies intended to treat primary ciliary dyskinesia. The private company is based in Menlo Park, CA. David J. Lockhart has been the CEO of the company since 2014. Transcriptx was acquired by ReCode Therapeutics, Inc. on March 26, 2020. | Director/Board Member | 01/01/2020 |
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Director of Finance/CFO | 01/01/2013 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Public Communications Contact | 01/01/2006 |
| JPMORGAN CHASE & CO. | Corporate Officer/Principal | - |
Formazione di Christopher Chai
| Cornell University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| JPMORGAN CHASE & CO. | Finance |
| SURROZEN, INC. | Health Technology |
| Aziende private | 7 |
|---|---|
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Transcriptx, Inc.
Transcriptx, Inc. BiotechnologyHealth Technology Part of ReCode Therapeutics, Inc., Transcriptx, Inc. develops mRNA therapies intended to treat primary ciliary dyskinesia. The private company is based in Menlo Park, CA. David J. Lockhart has been the CEO of the company since 2014. Transcriptx was acquired by ReCode Therapeutics, Inc. on March 26, 2020. | Health Technology |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One Capital Management LP (SR One) is a venture capital firm founded in 2020. The firm is headquartered in Redwood, California. | Finance |
- Borsa valori
- Insiders
- Christopher Chai
